Data Entry: Please note that the research database will be replaced by UNIverse by the end of October 2023. Please enter your data into the system Thanks

Login for users with Unibas email account...

Login for registered users without Unibas email account...

Effects of drug interactions on biotransformation and antiplatelet effect of clopidogrel in vitro
JournalArticle (Originalarbeit in einer wissenschaftlichen Zeitschrift)
ID 1194233
Author(s) Zahno, Anja; Brecht, Karin; Bodmer, Michael; Bur, Daniel; Tsakiris, Dimitrios A.; Krähenbühl, Stephan
Author(s) at UniBasel Bodmer, Michael
Tsakiris, Dimitrios
Brecht Brüngger, Karin
Krähenbühl, Stephan
Year 2010
Title Effects of drug interactions on biotransformation and antiplatelet effect of clopidogrel in vitro
Journal British journal of pharmacology
Volume 161
Number 2
Pages / Article-Number 393-404
Keywords clopidogrel, carboxylate metabolite of clopidogrel, CYP3A4, CYP2C19, drug interactions, R-130964
Mesh terms Aryl Hydrocarbon Hydroxylases, antagonists & inhibitors; Atorvastatin; Clarithromycin, pharmacology; Clopidogrel; Cytochrome P-450 CYP2C19; Cytochrome P-450 CYP3A; Cytochrome P-450 CYP3A Inhibitors; Drug Interactions; Enzyme Inhibitors, pharmacology; Heptanoic Acids, pharmacology; Humans; In Vitro Techniques; Ketoconazole, pharmacology; Microsomes, Liver, metabolism; Models, Molecular; Platelet Aggregation, drug effects; Platelet Aggregation Inhibitors, pharmacology; Platelet Count; Pyrroles, pharmacology; Recombinant Proteins, antagonists & inhibitors; Simvastatin, pharmacology; Substrate Specificity; Ticlopidine, pharmacology
Abstract The conversion of clopidogrel to its active metabolite, R-130964, is a two-step cytochrome P450 (CYP)-dependent process. The current investigations were performed to characterize in vitro the effects of different CYP inhibitors on the biotransformation and on the antiplatelet effect of clopidogrel.; Clopidogrel biotransformation was studied using human liver microsomes (HLM) or specific CYPs and platelet aggregation using human platelets activated with ADP.; Experiments using HLM or specific CYPs (3A4, 2C19) revealed that at clopidogrel concentrations <10 microM, CYP3A4 was primarily responsible for clopidogrel biotransformation. At a clopidogrel concentration of 40 microM, ketoconazole showed the strongest inhibitory effect on clopidogrel biotransformation and clopidogrel-associated inhibition of platelet aggregation with IC(50) values of 0.03 +/- 0.07 microM and 0.55 +/- 0.06 microM respectively. Clarithromycin, another CYP3A4 inhibitor, impaired clopidogrel biotransformation and antiplatelet activity almost as effectively as ketoconazole. The CYP3A4 substrates atorvastatin and simvastatin both inhibited clopidogrel biotransformation and antiplatelet activity, less potently than ketoconazole. In contrast, pravastatin showed no inhibitory effect. As clopidogrel itself inhibited CYP2C19 at concentrations <10 microM, the CYP2C19 inhibitor lansozprazole affected clopidogrel biotransformation only at clopidogrel concentrations > or =10 microM. The carboxylate metabolite of clopidogrel was not a CYP substrate and did not affect platelet aggregation.; At clopidogrel concentrations <10 microM, CYP3A4 is mainly responsible for clopidogrel biotransformation, whereas CYP2C19 contributes only at clopidogrel concentrations > or =10 microM. CYP2C19 inhibition by clopidogrel at concentrations <10 microM may explain the conflicting results between in vitro and in vivo investigations regarding drug interactions with clopidogrel.
Publisher Nature Publishing Group
ISSN/ISBN 0007-1188
Full Text on edoc No
Digital Object Identifier DOI 10.1111/j.1476-5381.2010.00881.x
PubMed ID
ISI-Number WOS:000281210400010
Document type (ISI) Journal Article

MCSS v5.8 PRO. 0.407 sec, queries - 0.000 sec ©Universität Basel  |  Impressum   |